RedHill Biopharma Ltd – (NASDAQ:RDHL) has earned an average rating of “Buy” from the seven brokerages that are covering the company. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $28.00.

Several equities research analysts have weighed in on RDHL shares. Zacks Investment Research upgraded RedHill Biopharma Ltd – from a “sell” rating to a “hold” rating in a report on Friday, August 26th. FBR & Co upped their target price on RedHill Biopharma Ltd – from $33.00 to $36.00 and gave the stock an “outperform” rating in a report on Wednesday, July 27th.

RedHill Biopharma Ltd – (NASDAQ:RDHL) traded down 0.327% during midday trading on Wednesday, hitting $14.652. The company had a trading volume of 19,252 shares. RedHill Biopharma Ltd – has a 52 week low of $8.10 and a 52 week high of $16.54. The stock’s market capitalization is $186.58 million. The stock has a 50 day moving average price of $15.12 and a 200-day moving average price of $12.55.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/redhill-biopharma-ltd-nasdaqrdhl-given-average-rating-of-buy-by-brokerages.html

RedHill Biopharma Ltd – (NASDAQ:RDHL) last posted its quarterly earnings data on Wednesday, July 27th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.52. On average, equities analysts predict that RedHill Biopharma Ltd – will post ($2.06) EPS for the current year.

Large investors have recently modified their holdings of the company. Van ECK Associates Corp boosted its stake in shares of RedHill Biopharma Ltd – by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock worth $105,000 after buying an additional 138 shares during the period. Ingalls & Snyder LLC bought a new stake in shares of RedHill Biopharma Ltd – during the second quarter worth $451,000. Oppenheimer & Co. Inc. bought a new stake in shares of RedHill Biopharma Ltd – during the second quarter worth $142,000. Finally, Royal Bank of Canada boosted its stake in shares of RedHill Biopharma Ltd – by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock worth $259,000 after buying an additional 191 shares during the period.

About RedHill Biopharma Ltd –

5 Day Chart for NASDAQ:RDHL

Receive News & Ratings for RedHill Biopharma Ltd - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd - and related companies with MarketBeat.com's FREE daily email newsletter.